Eltrombopag is one of the TPO-RAs approved for the treatment of ITP that binds to the transmembrane domain of the thrombopoietin receptor (MPL) and initiates the signaling cascades (JAK/STAT and MAPK) that are similar but not identical to those of endogenous TPO, that promote proliferation and differentiation from bone marrow progenitor cells to increase platelet production [7,8]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.